We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




New Sandwich Biosensor Developed for Tuberculosis Diagnosis and Screening

By LabMedica International staff writers
Posted on 07 Jun 2015
Print article
Researchers have developed a system that could quickly and reliably identify people infected with Mycobacterium tuberculosis and simultaneously differentiate from those who have received the bacillus Calmette-Guerin (BCG) vaccine for tuberculosis (TB).

Early identification is required to reduce the growing worldwide healthcare burden of TB. One of the biggest hurdles is to differentiate people infected with TB from those who have received the BCG vaccine. An international research team from Malaysia and Iran, led by Taha Roodbar Shojaei and Mohamad Amran Mohd Salleh of Universiti Putra Malaysia (Selangor, Malaysia), have developed a layered biosensor using modified quantum dots, gold nanoparticles, and single-strand DNAs (two specific oligonucleotides against early secretory antigenic target 6). The sensor not only detects TB in patient sputum but also differentiates positive results from samples of vaccinated people. The sensor requires small amounts of sputum and could therefore be used where limited sample volumes are available.

Using the new sensor, the team has conducted preliminary tests on 50 clinical samples from patients in Tehran who were suspected of having TB. While current PCR-based diagnostic TB tests have an approximately 80% success rate for both sensitivity and specificity, the sensor test (based on this initial sample set) had 94.2% sensitivity and 86.6 % specificity. Its unique advantages in terms of turnaround time, higher sensitivity and specificity, as well as a lower (10-fold) detection limit would recommend this test as a more appropriate and cost-effective tool for large scale operations.

In 2015, the team is working to further enhance the biosensor with carbon nanoparticles instead of gold. They also plan to develop the device and interface to further simplify detection, perhaps with a smartphone app.

The report, by Shojaei TR, et al, was published in the November-December 2014 issue of the Brazilian Journal of Infectious Diseases.

Related Links:

Universiti Putra Malaysia


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: Liquid biopsy could detect and monitor aggressive small cell lung cancer (Photo courtesy of Shutterstock)

Blood-Based Test Detects and Monitors Aggressive Small Cell Lung Cancer

Small cell lung cancer (SCLC) is a highly aggressive type of cancer known for its ability to metastasize. The behavior of tumors is largely governed by which genes are turned on, or transcribed, irrespective... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The groundbreaking treatment approach has shown promise in hard-to-treat cancers (Photo courtesy of 123RF)

Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment

Cancer treatment typically adheres to a standard of care—established, statistically validated regimens that are effective for the majority of patients. However, the disease’s inherent variability means... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.